Literature DB >> 15951986

Prophylactic and interventional granulocyte transfusions in patients with haematological malignancies and life-threatening infections during neutropenia.

Sabine Mousset1, Stella Hermann, Stefan A Klein, Heike Bialleck, Michaele Duchscherer, Barbara Bomke, Barbara Wassmann, Angelika Böhme, Dieter Hoelzer, Hans Martin.   

Abstract

Patients with haematological malignancies and prolonged periods of neutropenia after chemotherapy are at high risk for severe bacterial and fungal infections. Those infections have long time been considered as a contraindication for subsequent haematopoietic stem cell transplantation (HCT). We conducted a prospective, non-randomized study of granulocyte transfusions (GTX) to control acute life-threatening infections (44 episodes) and to prevent recurrence of severe fungal infections during HCT or intensive chemotherapy (23 episodes). GTX achieved control in 82% (36/44) of acute life-threatening infections. No single reactivation of a previous infection occurred under prophylactic GTX (0/23). Median survival was 170 days in the interventional group and 185 days in the prophylactic group; death in both patient groups was mainly due to underlying progressive malignant disease. We conclude that under GTX, the infection-related mortality even in high-risk patients is low. Due to a secondary prophylaxis with GTX, haematopoietic allografts can be safely given to patients with previous fungal infections.

Entities:  

Mesh:

Year:  2005        PMID: 15951986     DOI: 10.1007/s00277-005-1055-z

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  25 in total

1.  Granulocyte transfusion therapy: randomization after all?

Authors:  Agata Drewniak; Taco W Kuijpers
Journal:  Haematologica       Date:  2009-12       Impact factor: 9.941

2.  Invasive fungal infections in acute leukemia.

Authors:  Vijaya R Bhatt; George M Viola; Alessandra Ferrajoli
Journal:  Ther Adv Hematol       Date:  2011-08

Review 3.  Granulocyte transfusions: A concise review for practitioners.

Authors:  Juan Gea-Banacloche
Journal:  Cytotherapy       Date:  2017-09-12       Impact factor: 5.414

4.  How I transplant a patient with a history of invasive fungal disease.

Authors:  Pedro Puerta-Alcalde; Richard Champlin; Dimitrios P Kontoyiannis
Journal:  Blood       Date:  2020-08-26       Impact factor: 22.113

Review 5.  Therapeutic Challenges of Non-Aspergillus Invasive Mold Infections in Immunosuppressed Patients.

Authors:  Frederic Lamoth; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

6.  Use of healthy-donor granulocyte transfusions to treat infections in neutropenic patients with myeloid or lymphoid neoplasms: experience in 74 patients treated with 373 granulocyte transfusions.

Authors:  Amar Safdar; Gilhen Rodriguez; Jorge Zuniga; Fadi Al Akhrass; Anupam Pande
Journal:  Acta Haematol       Date:  2013-09-19       Impact factor: 2.195

7.  Granulocyte transfusions in severe aplastic anemia: an eleven-year experience.

Authors:  Karen Quillen; Edward Wong; Phillip Scheinberg; Neal S Young; Thomas J Walsh; Colin O Wu; Susan F Leitman
Journal:  Haematologica       Date:  2009-12       Impact factor: 9.941

Review 8.  How I treat mucormycosis.

Authors:  Dimitrios P Kontoyiannis; Russell E Lewis
Journal:  Blood       Date:  2011-05-26       Impact factor: 22.113

9.  Experimental evidence that granulocyte transfusions are efficacious in treatment of neutropenic hosts with pulmonary aspergillosis.

Authors:  Marife Martinez; Vicky Chen; Ann-Jay Tong; Kelsey Hamilton; Karl V Clemons; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2013-02-04       Impact factor: 5.191

10.  Efficacy of transfusion with granulocytes from G-CSF/dexamethasone-treated donors in neutropenic patients with infection.

Authors:  Thomas H Price; Michael Boeckh; Ryan W Harrison; Jeffrey McCullough; Paul M Ness; Ronald G Strauss; W Garrett Nichols; Taye H Hamza; Melissa M Cushing; Karen E King; Jo-Anne H Young; Eliot Williams; Janice McFarland; Jennifer Holter Chakrabarty; Steven R Sloan; David Friedman; Samir Parekh; Bruce S Sachais; Joseph E Kiss; Susan F Assmann
Journal:  Blood       Date:  2015-09-02       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.